Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition

Trial Profile

Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Agitation; Autistic disorder; Bipolar disorders; Gilles de la Tourette's syndrome; Major depressive disorder; Pervasive child development disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top